Home/ Stocks/ ATOS

Atossa Therapeutics, Inc. Common Stock

ATOS XNAS

$5.51 -0.20 (-3.52%) ▼ 15-min delayed

Open

$5.61

High

$5.69

Low

$5.39

Volume

41.3K

Market Cap

$48.31M

About Atossa Therapeutics, Inc. Common Stock

Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.

Sector: PHARMACEUTICAL PREPARATIONS Employees: 13 Website →

Key Financials

Period	Revenue	Net Income	EPS
Q3 2025	$0	$-8,692,000	$-0.07
Q2 2025	$0	$-8,423,000	$-0.07
Q1 2025	$0	$-6,718,000	$-0.05
FY 2024	$0	$-25,504,000	$-0.20

Earnings & Analyst Ratings

Next Earnings: Mon, May 11, 2026

Calendar →

Related Market News

No specific coverage for ATOS yet. Check out our latest market news or earnings calendar.

Get ATOS Alerts

Stay ahead with breaking news, price alerts, and expert analysis on Atossa Therapeutics, Inc. Common Stock.

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.